Literature DB >> 1687776

Adult forms of metachromatic leukodystrophy: clinical and biochemical approach.

N Baumann1, M Masson, V Carreau, M Lefevre, N Herschkowitz, J C Turpin.   

Abstract

The clinical and biochemical characteristics of metachromatic leukodystrophy (MLD), true adult forms and late juvenile forms which are still living at adulthood, are reviewed as they both are observed in adult Neurology and Psychiatry departments. Mental deterioration is often the first symptom, evolving progressively; and dementia finally occurs. The latency before the appearance of neurological objective symptoms may be long and extend for several years. In many cases, the behavioral abnormalities are the first symptoms. Some of these forms have been diagnosed as schizophrenia. Very seldom, neurological symptoms, especially ataxia, occur without cognitive or psychiatric disturbances. Most of these cases have pyramidal and cerebellar symptoms, at diverse degrees. Seizures can also occur which is some cases can be early symptoms associated to mental deterioration. The association of central and peripheral neurological symptoms is very characteristic of MLD. The peripheral neuropathy is not generally clinically evidenced, but is rarely missing electrophysiologically. Arylsulfatase A determination should be performed for diagnosis as a first step, and confirmed by the accumulation of sulfatide, either by quantitative determinations in urine or by the sulfatide loading test. It is as yet not clear why certain forms have a rather rapid evolution in 5 years, and others have a very protracted course during decades.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1687776     DOI: 10.1159/000112162

Source DB:  PubMed          Journal:  Dev Neurosci        ISSN: 0378-5866            Impact factor:   2.984


  10 in total

Review 1.  Inborn errors of metabolism as a cause of neurological disease in adults: an approach to investigation.

Authors:  R G Gray; M A Preece; S H Green; W Whitehouse; J Winer; A Green
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-07       Impact factor: 10.154

Review 2.  Screening for lysosomal disorders.

Authors:  K Ullrich
Journal:  Eur J Pediatr       Date:  1994       Impact factor: 3.183

3.  Rare Diseases in Glycosphingolipid Metabolism.

Authors:  Hongwen Zhou; Zhoulu Wu; Yiwen Wang; Qinyi Wu; Moran Hu; Shuai Ma; Min Zhou; Yan Sun; Baowen Yu; Jingya Ye; Wanzi Jiang; Zhenzhen Fu; Yingyun Gong
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

Review 4.  Hereditary spastic paraparesis in adults associated with inborn errors of metabolism: a diagnostic approach.

Authors:  F Sedel; B Fontaine; J M Saudubray; O Lyon-Caen
Journal:  J Inherit Metab Dis       Date:  2007-10-22       Impact factor: 4.982

Review 5.  Psychiatric manifestations revealing inborn errors of metabolism in adolescents and adults.

Authors:  F Sedel; N Baumann; J-C Turpin; O Lyon-Caen; J-M Saudubray; D Cohen
Journal:  J Inherit Metab Dis       Date:  2007-08-10       Impact factor: 4.982

Review 6.  Adulthood leukodystrophies.

Authors:  Wolfgang Köhler; Julian Curiel; Adeline Vanderver
Journal:  Nat Rev Neurol       Date:  2018-01-05       Impact factor: 42.937

7.  White matter abnormalities and animal models examining a putative role of altered white matter in schizophrenia.

Authors:  Haiyun Xu; Xin-Min Li
Journal:  Schizophr Res Treatment       Date:  2011-08-11

Review 8.  Psychiatric manifestations of treatable hereditary metabolic disorders in adults.

Authors:  Caroline Demily; Frédéric Sedel
Journal:  Ann Gen Psychiatry       Date:  2014-09-24       Impact factor: 3.455

9.  An insight into the biochemistry of inborn errors of metabolism for a clinical neurologist.

Authors:  Rita Christopher; Bindu P Sankaran
Journal:  Ann Indian Acad Neurol       Date:  2008-04       Impact factor: 1.383

Review 10.  Leukoencephalopathies associated with inborn errors of metabolism in adults.

Authors:  F Sedel; A Tourbah; B Fontaine; C Lubetzki; N Baumann; J-M Saudubray; O Lyon-Caen
Journal:  J Inherit Metab Dis       Date:  2008-02-25       Impact factor: 4.750

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.